-- As of September 2026, Nuropod celebrates the one-year milestone since the launch of Nuropod, a wearable nervous system wellness device built on over a decade of clinical research through its proprietary AVNT™ neuromodulation technology. The one-year anniversary of Nuropod's release comes amid growing attention to stress and nervous system health, as more people look for ways to support recovery and everyday resilience. Parasym seeks to address this shift, positioning Nuropod as a wearable option designed to support the nervous system.
The device is a small, tragus-worn wearable that delivers mild electrical pulses through AVNT to the point where the vagus nerve reaches the skin of the ear. The vagus nerve carries signals between the brain and organs including the heart, lungs and gut, and plays a large role in how the body manages stress, rest and recovery.
Most people use the device for around 30 minutes, once or twice a day, while working, reading or watching television. The device is classified as a wellness device rather than a medical device, and is designed to be used alongside a person's existing care, not in place of it. It is also FCC-compliant, with a 30-day return guarantee.
Parasym's AVNT technology, used in Nuropod and in its sister device Nurosym, has been evaluated in more than 60 completed studies with more than 150 research partners, according to the company. Many of those studies involved clinical populations, such as people with long COVID, POTS or heart failure, rather than general wellness users.
"The autonomic nervous system, particularly the vagus nerve, plays a key role in regulating the balance between stress response and recovery," said Dr Elisabetta Burchi, Head of Research at Parasym. "Supporting our vagal tone may help regulate inflammatory response, support recovery from sleep disruption, and improve overall resilience."
About Parasym
Parasym is the research company behind Nuropod, holding the AVNT patent underpinning the device's technology. Nuropod has operated in the United States market since September 2025. Additional information on Nuropod's research programme and product line is available at https://nuropod.com/
Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.
Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/
Release ID: 89206680